The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer

Basit Öğe Kaydı
dc.contributor.authorKarpuz, Tuba
dc.contributor.authorAraz, Murat
dc.contributor.authorKorkmaz, Levent
dc.contributor.authorKilinc, Ibrahim
dc.contributor.authorFindik, Sidika
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorEryilmaz, Melek Karakurt
dc.date.accessioned2024-02-23T13:59:45Z
dc.date.available2024-02-23T13:59:45Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractPurpose Despite new treatment options in metastatic colorectal cancer (mCRC), new prognostic markers are still needed to determine optimal chemoregimen especially for anti-angiogenesis drugs. In this study, we evaluated the serum semaphorin and VEGF-A levels as prognostic factors in patients with mCRC. Methods Patients with diagnosed mCRC who were treated with first-line bevacizumab plus chemotherapy were included in the study. Venous blood samples of 37 patients with metastatic colon cancer were taken, and serum semaphorin 3A and VEGF-A levels were studied in pre-treatment and the 1st and third months after the treatment was initiated. Results Totally, 37 patients were enrolled in the study. The patients' mean age was 62 years. Twenty-eight (49%) of the patients were male, and 19 (51%) were female. Serum semaphorin3A (sema3A) levels of the patients were 5.4 +/- 7.4 ng/ml before the treatment, 3.5 +/- 3.3 ng/ml at the first month, and 3.5 +/- 3.7 ng/ml at the third month. Serum VEGF-A levels were 27.7 +/- 32.9 ng/l before the treatment, 23.1 +/- 28.1 ng/l at the first month, and 28.9 +/- 30.2 ng/l at the third month. There was no significant correlation between the survival and pre-treatment VEGF-A level (p = 0.064). Overall survival (OS) was statistically significantly higher in patients with pre-treatment semaphorin 3A levels below 5.4 ng/ml than higher than 5.4 ng/ml (10.5 months vs 4.5 months, respectively, HR 0.23, 95% CI 19.635-11,391, p = 0.012). Conclusion Pre-treatment semaphorin 3A level can be a prognostic marker for the mCRC patients who were treated with bevacizumab in patients with metastatic colorectal cancer.en_US
dc.description.sponsorship151518014 [1] Funding Source: Medlineen_US
dc.identifier.doi10.1007/s12029-019-00263-4
dc.identifier.endpage497en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue2en_US
dc.identifier.pmid31218581en_US
dc.identifier.scopus2-s2.0-85067864426en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage491en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-019-00263-4
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11308
dc.identifier.volume51en_US
dc.identifier.wosWOS:000531030000015en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectSemaphorin3aen_US
dc.subjectVascular Endothelial Growth Factoren_US
dc.titleThe Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu